CNTA Stock Overview
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients.
Centessa Pharmaceuticals plc Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$4.02|
|52 Week High||US$17.73|
|52 Week Low||US$2.89|
|1 Month Change||-7.59%|
|3 Month Change||-22.24%|
|1 Year Change||-75.67%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-81.52%|
Recent News & Updates
Centessa hemophilia B therapy SerpinPC gets FDA orphan drug status
The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Centessa Pharmaceuticals' (NASDAQ:CNTA) SerpinPC to treat hemophilia B. The U.K.-based company said in a Sept. 14 press release that it plans to begin registrational studies of SerpinPC in Q4 2022. SerpinPC is a biological drug candidate, based on the serpin family of proteins which is designed to allow more thrombin to be generated by inhibiting activated protein C (APC), thus rebalancing coagulation in patients with hemophilia, according to Centessa. "We believe SerpinPC has the potential to offer patients with hemophilia B a convenient subcutaneous option that is designed to prevent and reduce bleeds without the risk of thrombosis," said Centessa CEO Saurabh Saha. The FDA grants orphan drug status to therapies which treat or prevent rare diseases that affect fewer than 200K people in the U.S. The designation provides certain incentives, including up to seven years of market exclusivity, if approved.
Centessa Pharmaceuticals GAAP EPS of -$0.69
Centessa Pharmaceuticals press release (NASDAQ:CNTA): Q2 GAAP EPS of -$0.69. Cash and Cash Equivalents: $484.2 million as of June 30, 2022, which the Company expects will fund operations into 2026, without drawing on the remaining available tranches under the Oberland credit facility.
|CNTA||US Biotechs||US Market|
Return vs Industry: CNTA underperformed the US Biotechs industry which returned -25.8% over the past year.
Return vs Market: CNTA underperformed the US Market which returned -21.5% over the past year.
|CNTA Average Weekly Movement||12.9%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: CNTA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: CNTA's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases.
Centessa Pharmaceuticals plc Fundamentals Summary
|CNTA fundamental statistics|
Is CNTA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CNTA income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.33|
|Net Profit Margin||0.00%|
How did CNTA perform over the long term?See historical performance and comparison